How should naturally occurring mutations be represented in nucleic acid sequences?

Question

Accepted Answer

Source: FAQ (MPEP-Based) BlueIron Update: 2024-09-30 10 Rules 5 Related FAQs This page is an FAQ based on guidance from the Manual of Patent Examining Procedure. It is provided as guidance, with links to the ground truth sources. This is information only: it is not legal advice. According to the table in MPEP 2412.05(c) , naturally occurring mutations in nucleic acid sequences should be represented as follows: Feature Key: variation Qualifier: replace or note Use: For naturally occurring mutations and polymorphisms, such as alleles and RFLPs (Restriction Fragment Length Polymorphisms) This representation allows for proper documentation of genetic variations in patent applications related to biotechnology. Related Rules from the Manual of Patent Examining Procedure 10 rules Collapse Representation of Sequence Variants in Sequence Listing XML Required MPEP 2412.05(c) Sequence Listing Must Be In XML Format MPEP 2412 Required Single Sequence Listing for All IPOs MPEP 2412 Permitted Sequence Data Must Be Presented in Standardized XML Format MPEP 2412 Contact USPTO for Patent Application Inspection MPEP 2412 Source for Sequence Listing Required MPEP 2412 Permitted Sequence Listing Must Be In XML Format MPEP 2412 Sequence Listing Must Be In XML Format MPEP 2412 Permitted Proper Use of Feature Keys and Qualifiers for Sequence Variants MPEP 2412.05(c) Disclosure of Nucleotide and Amino Acid Sequences Required MPEP 2412.05(c) Other Related FAQs 5 FAQs Collapse When is the MPEP 2412.05(c) guidance on sequence variants applicable? How should amino acid sequence variants produced by alternative splicing be represented? How are artificially introduced variations in nucleic acid sequences represented? What is the proper representation for other types of amino acid variants? What are the requirements for representing sequence variants in a &#8220;Sequence Listing XML&#8221;?